https://www.selleckchem.com/pr....oducts/oxalacetic-ac
For the 631 patients with cardiomyopathy, tafamidis treatment was associated with a longer median MCO-free survival time (n=98) 1565 (1010-240 days vs. 771 (686-895) days without treatment (log-rank P 0.001). This association was confirmed after considering confounding factors (age at inclusion, N-terminal pro-B-type natriuretic peptide and amyloidosis type) with a propensity score (hazard ratio 0.546; P=0.0132). In a large cohort of ATTRwt and ATTRv patients, representative of the inclusion criteria of the ATTR-ACT trial
Like
Comment
Share
